Side Effects of Immunotherapy
Immunotherapy is an approach to cancer treatment that uses the body’s own immune system to fight malignant cells. While often effective, it can also lead to a range of immunotherapy side effects, which differ from those associated with traditional chemotherapy.
Key Takeaways
- Immunotherapy side effects, known as immune-related adverse events, occur when the activated immune system targets healthy tissues.
- These reactions can be systemic (affecting the whole body) or organ-specific, and their severity ranges from mild to serious.
- Prompt communication with your care team is important for effective management, since early attention can help prevent a symptom from escalating.
- Some patients experience long-term effects of immunotherapy, which may call for ongoing monitoring and management.
- Patient-specific factors and the type of immunotherapy used can both influence the likelihood and severity of side effects.
Common Immunotherapy Side Effects Explained
Unlike chemotherapy, which directly targets rapidly dividing cells, immunotherapy works by stimulating the immune system. This activation can sometimes lead the immune system to also target healthy cells and tissues, resulting in immune-related adverse events.
These reactions can affect almost any organ system, and their onset can range from days to months after treatment begins.
Systemic vs. Organ-Specific Reactions
Immunotherapy side effects can be broadly grouped into systemic and organ-specific reactions. Systemic reactions affect the whole body and are often among the first to appear; these commonly include fatigue, flu-like symptoms such as fever and chills, and muscle or joint aches.
Organ-specific reactions target particular organs or tissues, leading to more localized symptoms. The skin, gastrointestinal tract, endocrine glands, and lungs are among the more frequently affected sites — for example, skin rash, diarrhea or colitis (inflammation of the colon), and thyroid or other endocrine gland changes are commonly reported, while inflammation of the lungs, liver, or other organs is less common.
Understanding Immune-Related Adverse Events
Immune-related adverse events are the hallmark of immunotherapy side effects. They happen because an overactivated immune system loses some of its ability to tell cancerous cells apart from healthy ones. The specific type of immunotherapy used — such as a checkpoint inhibitor targeting PD-1, PD-L1, or CTLA-4 — can influence which side effects are more likely.
Most immune-related adverse events are mild to moderate and can be managed with monitoring and, if needed, medication. Severe or life-threatening allergic and inflammation-related reactions can occur, but they are rare. Recognizing symptoms early and reporting them promptly are what keep most reactions from becoming more serious.
Managing Immunotherapy Adverse Reactions
Effectively managing immunotherapy adverse reactions is a cornerstone of successful treatment. It calls for a proactive approach from both the patient and the healthcare team, with an emphasis on early detection and timely action. The goal is to control symptoms and prevent complications while continuing immunotherapy whenever that remains possible.
When to Contact Your Care Team
Patients should be informed about potential immunotherapy side effects and encouraged to report any new or worsening symptoms right away, since these reactions can escalate quickly if left unaddressed. Contact your care team if you experience:
- New or worsening fatigue, fever, or chills.
- Skin rash, itching, or blistering.
- Persistent diarrhea, severe abdominal pain, or blood in the stool.
- New or worsening cough, shortness of breath, or chest pain.
- Severe headaches, vision changes, or confusion.
- Significant muscle weakness or joint pain.
- Any other symptom that causes concern or affects daily activities.
Your care team will give you specific guidance on which symptoms need immediate attention, often including a contact number for urgent concerns outside regular hours.
Strategies for Symptom Relief
Management strategies depend on the severity of the reaction and which organ system is affected. Milder reactions may be managed with supportive care alone, while moderate to severe reactions often call for more active treatment, which can include:
- Corticosteroids: These are the primary treatment for most moderate to severe immune-related reactions, working by suppressing the overactive immune response. How long they’re used, and at what dose, is tailored to the specific reaction and its severity.
- Other immune-suppressing medicines: For reactions that don’t respond well to corticosteroids alone, additional immune-suppressing treatment may be considered.
- Symptom-directed care: This includes supportive treatment for nausea, pain, or itching, tailored to what the patient is experiencing.
- Pausing or stopping treatment: In more severe cases, immunotherapy may need to be paused temporarily, or in some cases stopped altogether, to allow the immune system to settle.
Coping with immunotherapy side effects also often involves everyday adjustments, such as staying well hydrated, eating a balanced diet, and staying as active as tolerated. Psychological support and patient education are also valuable parts of comprehensive care.
Long-Term Immunotherapy Effects
While many immunotherapy side effects resolve after treatment ends or with appropriate management, some patients experience long-term effects of immunotherapy. These can persist for months after the last dose, or emerge later as late-onset complications.
Persistent Symptoms and Monitoring
Chronic immune-related reactions can meaningfully affect a person’s quality of life. Fatigue and endocrine changes — particularly thyroid gland changes — are among the more commonly reported persistent effects. Thyroid changes such as an underactive thyroid can become a long-term condition requiring hormone replacement therapy.
Ongoing monitoring matters for anyone who has completed immunotherapy, especially those who had immune-related reactions during treatment. This typically includes regular blood tests to check hormone levels and organ function, along with continued attention to any new or recurring symptoms. A care team that extends beyond oncology — for example, including an endocrinologist or dermatologist — is sometimes needed to manage these longer-term effects.
Late-Onset Complications
In some cases, immune-related reactions can appear months or even years after immunotherapy has ended. These late-onset complications are less common, but they highlight why continued awareness matters even after active treatment stops. Patients and their care teams should stay alert to unusual new symptoms long after treatment has concluded, to support timely diagnosis and management.
Factors Influencing Treatment Risks
Several factors can influence how likely a person is to experience immunotherapy side effects, and how severe those effects might be. These fall broadly into patient-specific factors and factors related to the type of immunotherapy itself.
Patient-Specific Variables
Individual characteristics play a meaningful role in a person’s likelihood of experiencing immunotherapy side effects, including:
- Pre-existing autoimmune conditions: People with a history of autoimmune disease may be at higher risk of more pronounced immune-related reactions, since their immune system is already more prone to affecting healthy tissue.
- Age: Immunotherapy is generally well tolerated across age groups, though older patients may have other health conditions that can influence how side effects present and are managed.
- Overall health: Patients with significant organ dysfunction or multiple coexisting conditions may be more vulnerable to severe reactions and may have less capacity to recover from them.
Type of Immunotherapy and Dosage
The specific immunotherapy agent, or combination of agents, is a key factor in the risk and pattern of side effects, since different drug classes act on different parts of the immune system.
Combining more than one type of immune checkpoint inhibitor — for example, one targeting CTLA-4 together with one targeting PD-1 — is used for certain cancers, but using more than one at the same time can also change the pattern and severity of side effects a person experiences compared with a single agent. This is one of several factors an oncology team weighs when recommending a specific immunotherapy regimen, alongside the expected benefit for a given cancer type.
Frequently Asked Questions
How long do immunotherapy side effects last?
The duration varies a great deal from person to person. Many mild to moderate effects resolve within weeks to months of treatment ending, or with appropriate management. Some patients experience persistent symptoms for longer; endocrine changes such as an underactive thyroid often require long-term hormone replacement. Late-onset complications can also emerge months or years after treatment, which is why ongoing monitoring matters.
Can immunotherapy side effects be prevented?
Completely preventing immunotherapy side effects usually isn’t possible, since they’re a byproduct of activating the immune system. However, their impact can often be reduced through proactive monitoring, early symptom recognition, and prompt treatment with corticosteroids or other immune-suppressing medicines when needed. Reporting new symptoms to your care team right away is one of the most effective ways to keep a minor issue from becoming more serious.
Is immunotherapy more dangerous than chemotherapy?
Comparing the two isn’t straightforward, since each has a distinct side effect profile. Chemotherapy typically causes more immediate, predictable side effects tied to its effect on rapidly dividing cells throughout the body. Immunotherapy’s risks come from immune system overactivation, which can affect any organ and sometimes appear later than expected. Immune-related reactions can be serious, but they are often manageable with immune-suppressing medication. Which treatment carries more risk for a given person depends on the specific drug, cancer type, and individual health factors — it’s a question best discussed with your oncology team.
Sources
